Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EL03
|
| gptkbp:CASNumber |
1691249-45-6
|
| gptkbp:chemicalFormula |
C27H29N5O3
|
| gptkbp:developedBy |
gptkb:BeiGene
|
| gptkbp:drugClass |
BTK inhibitor
|
| gptkbp:genericName |
zanubrutinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Brukinsa
|
| gptkbp:indication |
gptkb:mantle_cell_lymphoma
gptkb:small_lymphocytic_lymphoma gptkb:Waldenström's_macroglobulinemia chronic lymphocytic leukemia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:China
gptkb:European_Union gptkb:United_States |
| gptkbp:mechanismOfAction |
Bruton's tyrosine kinase inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
rash neutropenia thrombocytopenia upper respiratory tract infection |
| gptkbp:bfsParent |
gptkb:BeiGene
|
| gptkbp:bfsLayer |
7
|